PFE - ViiV Healthcare's cabotegravir successful in HIV prevention study May, 18 2020 07:06 AM Pfizer Inc. ViiV Healthcare announces positive preliminary results from the HIV Prevention Trials Network 083 study evaluating cabotegravir for the prevention of HIV infection.More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Healthcare stocks news, Read more ...